AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
82.34
+0.11 (0.13%)
At close: Oct 30, 2025, 4:00 PM EDT
81.99
-0.35 (-0.43%)
After-hours: Oct 30, 2025, 7:59 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.53
Revenue / Employee
$608,192
Employees
92,900
Market Cap
255.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Abbott Laboratories | 43.84B |
AZN News
- 6 days ago - AstraZeneca found in breach of industry code over Symbicort marketing, industry body says - Reuters
- 10 days ago - AstraZeneca hails major breakthroughs with breast-cancer drugs - Market Watch
- 12 days ago - AstraZeneca's Datroway extends survival in aggressive breast cancer - Reuters
- 12 days ago - AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment - Reuters
- 13 days ago - TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps - Business Wire
- 13 days ago - US FDA expands use of Amgen, AstraZeneca's drug for sinus infection - Reuters
- 15 days ago - AstraZeneca unveils expanded manufacturing facility in Texas - Business Wire
- 17 days ago - AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO - Business Wire